Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial

SIMPLE SUMMARY: The lung immune prognostic index (LIPI) is proposed as a simple risk scoring tool to differentiate differences in survival from immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC). The tool has not been evaluated for performance in a NSCLC cohort initia...

Descripción completa

Detalles Bibliográficos
Autores principales: Hopkins, Ashley M., Kichenadasse, Ganessan, Abuhelwa, Ahmad Y., McKinnon, Ross A., Rowland, Andrew, Sorich, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967121/
https://www.ncbi.nlm.nih.gov/pubmed/33803256
http://dx.doi.org/10.3390/cancers13051176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967121/
https://www.ncbi.nlm.nih.gov/pubmed/33803256
http://dx.doi.org/10.3390/cancers13051176

Ejemplares similares